Selenium is a trace mineral incorporated into selenoproteins — a special class of proteins that use selenocysteine (the 21st amino acid) at their active sites. Unlike most trace minerals, selenium's therapeutic window is notably narrow: deficiency causes serious disease, but toxicity occurs at levels only a few times above the recommended intake.
Understanding what selenium actually does explains why dosing precision matters more than with most micronutrients.
What selenium does: the selenoproteins
Selenium functions through ~25 selenoproteins in humans. The most clinically relevant:
Glutathione peroxidases (GPx1–4, GPx6): Enzymes that reduce hydrogen peroxide and lipid peroxides using glutathione. This is the primary antioxidant defense against oxidative damage to cell membranes and DNA. GPx4 specifically protects against ferroptosis — an iron-dependent cell death mechanism increasingly linked to cancer and neurodegeneration.
Thioredoxin reductases (TrxR): Reduce thioredoxin, maintaining the cellular redox state. Critical for DNA synthesis (ribonucleotide reductase function), immune signaling, and gene regulation.
Iodothyronine deiodinases (Dio1-3): Convert T4 (inactive thyroid hormone) to T3 (active) and reverse-T3. Without adequate selenium, thyroid hormone metabolism is impaired — selenium deficiency can present as or worsen hypothyroidism even with adequate iodine.
Selenoprotein P (SelP): Primary selenium transport protein in plasma. Also has antioxidant properties in extracellular fluid.
Methionine sulfoxide reductase B1: Repairs oxidatively damaged methionine residues in proteins.
Geography of deficiency
Selenium content in soil varies enormously by region — more than any other mineral. Crop selenium content reflects soil selenium directly.
High selenium regions: Great Plains (US), much of Canada, parts of South America.
Low selenium regions: Most of Europe, parts of China, New Zealand (historically), sub-Saharan Africa, parts of the UK.
Keshen disease — a severe cardiomyopathy and heart failure caused by selenium deficiency — was endemic in parts of China with near-zero soil selenium. Nationalized selenium supplementation in China's affected regions dramatically reduced Keshen disease incidence.
Keshan-Beck disease: another selenium deficiency disorder causing osteoarthropathy, also endemic in low-selenium Chinese regions.
European intake: European dietary selenium intakes are significantly lower than North American. UK, Scandinavia, and central European intakes often fall below RDA levels — a genuine public health concern that's under-recognized.
Optimal intake
RDA: 55mcg/day (adults)
Upper limit (UL): 400mcg/day
Selenium saturation: Plasma selenoprotein P reaches a plateau at approximately 70–80mcg/day dietary selenium in most populations. Beyond saturation, excess selenium accumulates in tissues and plasma as inorganic selenite — not a selenoprotein.
Key principle: The RDA is the intake needed to saturate selenoprotein P activity. Higher intakes don't produce more selenoprotein activity — they just accumulate as selenite.
Thyroid health evidence
Selenium and Hashimoto's:
Multiple RCTs show selenium supplementation reduces thyroid peroxidase antibodies (TPO-Ab) in Hashimoto's thyroiditis patients:
Fantz et al. and Gartner et al. (2002): 200mcg/day selenium (as selenomethionine) for 3–6 months reduced TPO-Ab levels by 30–40% in Hashimoto's patients vs. placebo.
Meta-analysis (Winther et al., 2020): Selenium supplementation significantly reduced TPO-Ab in Hashimoto's patients. Debate remains about clinical significance — antibody reduction doesn't definitively correlate with symptom improvement or progression to hypothyroidism.
Current status: Most endocrinology guidelines don't recommend selenium for Hashimoto's, but the evidence is strong enough that many practitioners prescribe 100–200mcg/day as an adjunct, particularly in selenium-deficient regions.
Selenium for Graves' disease:
Marcocci et al. (2011, NEJM): 200mcg/day selenium significantly improved mild Graves' orbitopathy (thyroid eye disease) vs. placebo after 6 months. This is one of the more convincing adjunct therapy RCTs in autoimmune thyroid disease.
Cancer prevention — the complicated story
The SELECT trial (Selenium and Vitamin E Cancer Prevention Trial) tested selenium (200mcg/day as selenomethionine) and vitamin E for prostate cancer prevention in 35,533 men:
Result: Selenium did not reduce prostate cancer risk. High-dose vitamin E actually increased prostate cancer risk.
Prior to SELECT, observational studies strongly suggested selenium was anti-cancer. The NHANES III data showed an inverse relationship between selenium status and cancer mortality. The Nutritional Prevention of Cancer trial (Clark et al., 1996) showed 200mcg/day selenium reduced cancer mortality by 50% in selenium-deficient subjects.
Why the discrepancy?
The Clark trial was conducted in a selenium-deficient population. SELECT enrolled men who were not selenium-deficient — their baseline selenium was already adequate. Supplementation in replete subjects produced no additional benefit and may have caused harm at the margin.
The conclusion: Selenium supplementation may reduce cancer risk in deficient populations; it does not benefit and may harm selenium-replete individuals at high doses.
Cardiovascular evidence
Low selenium status is associated with higher cardiovascular disease risk in observational studies. The Linxian Nutrition Intervention Study (China) showed selenium + vitamin E supplementation reduced cardiovascular mortality in selenium-deficient populations.
In selenium-replete Western populations, supplementation trials are less convincing. Meta-analyses show inconsistent effects.
Pattern: Same as cancer — benefit in deficient populations, limited or null benefit in replete populations.
Selenium toxicity (selenosis)
Acute selenium toxicity occurs at doses well above the UL. Chronic excess (>400mcg/day) causes:
- Brittle nails and hair loss (earliest signs)
- Garlic breath (from dimethylselenide exhalation)
- Peripheral neuropathy
- Fatigue, irritability
- Liver and kidney damage at very high doses
The narrow window: The UL of 400mcg/day is only 7× the RDA. Compare: vitamin C UL is 2,000mg vs. RDA of 90mg — a 22× range. Selenium's margin of safety is much smaller.
The 200mcg supplement trap: Many selenium supplements are sold at 200mcg — 3.6× the RDA and halfway to the UL. This is pharmacological, not nutritional. Safe for short-term use in deficient people; concerning as a chronic supplement in replete people.
Dietary sources
| Source | Selenium content |
|---|---|
| Brazil nuts (1 nut) | 68–91mcg — highly variable |
| Tuna, canned (3oz) | ~63mcg |
| Halibut (3oz) | ~47mcg |
| Sardines (3oz) | ~45mcg |
| Ham (3oz) | ~42mcg |
| Shrimp (3oz) | ~34mcg |
| Beef (3oz) | ~33mcg |
| Chicken breast (3oz) | ~22mcg |
| Egg (1 large) | ~15mcg |
| Brown rice (1 cup) | ~19mcg |
Brazil nut warning: Selenium content varies 10-fold between nuts and batches. Eating 3–4 Brazil nuts daily can approach or exceed the UL. One or two Brazil nuts as an occasional selenium source is reasonable; chronic daily consumption of handfuls is how people develop selenosis from food.
Supplementation guidance
If supplementing:
- 55–100mcg/day is adequate for most purposes — don't reflexively take 200mcg
- Selenomethionine form has better bioavailability than selenite or selenate
- Relevant populations: Europeans with low dietary intake, vegetarians/vegans (lower animal product selenium), people with Hashimoto's (100–200mcg as medical adjunct)
What to avoid:
- Chronic high-dose supplementation (200mcg/day) without deficiency indication
- Multiple selenium-containing supplements (many multivitamins include 55–100mcg; adding a separate selenium supplement may push total above UL)
- Daily Brazil nuts as a selenium strategy (too variable)
The framework applied
For any selenium study:
- What was baseline selenium status? Deficient vs. replete populations have completely opposite results
- What form? Selenomethionine, selenite, selenate — different bioavailability
- What dose? 55mcg (RDA) vs. 200mcg vs. 400mcg — different clinical contexts
- What outcome? Thyroid antibodies, cancer prevention, cardiovascular, antioxidant markers — different evidence bases
We automated this at Q-SCI. Any study — paste it, get a quality score.
Bottom line
- Selenium is essential for glutathione peroxidase (antioxidant defense) and thyroid hormone conversion — fundamental functions, not marketing
- RDA: 55mcg/day; UL: 400mcg — the narrowest therapeutic window of common micronutrients
- Thyroid: strongest human evidence — 200mcg/day reduces TPO antibodies in Hashimoto's; improves Graves' orbitopathy
- Cancer prevention evidence shows benefit in deficient populations; SELECT trial showed no benefit (and potential harm) in replete people — dose to needs, not maximally
- 200mcg supplements are 3.6× RDA — appropriate for documented deficiency or Hashimoto's adjunct, not as a routine supplement in selenium-adequate people
- Brazil nuts: highly variable selenium; one or two occasionally is fine, not as a daily megadose strategy
- Best forms: selenomethionine > selenate > selenite
More evidence-based analyses at q-sci.org/blog. Score studies free at q-sci.org.
Top comments (0)